MedTrace Logo

RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients

NCT05961943 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-04-09

No results posted yet for this study

Summary

The RESPONSE-2- peripheral arterial disease (PAD) program will be implemented to modify sedentary time in patients with PAD. It is an adapted version of the RESPONSE that aims to reduce sedentary behavior in individuals with diabetes. The RESPONSE-2-PAD is a multicomponent program involves an online educational component, sedentary reminders and health coaching sessions, which are designed to modify patients' sedentary behavior.

Conditions

  • Peripheral Arterial Disease
  • Sedentary Behavior
  • Sedentary Time
  • Peripheral Arterial Occlusive Disease

Interventions

BEHAVIORAL

RESPONSE-2-PAD

The RESPONSE-2-PAD program will undergo evaluation through a pilot study includes 50 patients living with peripheral arterial disease. Participants will take part in an initial assessment which will measure their sedentary time/physical activity using activPAL and their six-minute walking distance. They will then take part in a 12-week tailored, coaching-based intervention delivered remotely. The intervention involves the use of an activity tracker (sedentary reminder) and an online structured education program coupled with coaching calls that review sedentary time and activity goals weekly. At 12-weeks all participants will be invited to a follow up assessment. Participants will also be invited to take part in a semi-structured interview to explore their views and opinions of the program and its acceptability. At six months all patients will be invited for a final follow-up measurements.

Sponsors & Collaborators

  • National Institute for Prevention and Cardiovascular Health, Ireland

    lead OTHER

Principal Investigators

  • Jennifer Jones · University of Galway

  • Wael Tawfick · University of Galway

  • Charlotte Edwardson · University of Leicester

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-29
Primary Completion
2025-01-31
Completion
2025-08-31

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05961943 on ClinicalTrials.gov